Gloucester Pharmaceuticals, Inc. to Present Positive Results from Multiple Studies of ISTODAX(R) at the American Society of Hematology Annual Meeting
Published: Nov 25, 2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals today announced multiple presentations from clinical and preclinical studies of ISTODAX® (romidepsin) at the upcoming 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, Louisiana, at the Ernest N. Morial Convention Center, December 5 – 8, 2009. ISTODAX, a novel histone deacetylase (HDAC) inhibitor, was recently approved by the U.S. Food and Drug Administration for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. Additionally, Gloucester is currently conducting a registration trial in peripheral T-cell lymphoma (PTCL) and studies of ISTODAX are being conducted in other hematologic and solid tumors. ISTODAX is not FDA approved for the treatment of PTCL or other indications.